• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.

作者信息

Schmitz Jena, Gaskill Eric, Price Samantha, Cao Biwei, Kim Jongphil, Baluch Aliyah, Klinkova Olga, Faramand Rawan, Mishra Asmita, Perez Lia, Khimani Farhad, Lazaryan Aleksandr, Ochoa-Bayona Jose L, Liu Hien, Mirza Abu-Sayeef, Nieder Michael, Anasetti Claudio, Nishihori Taiga, Pidala Joseph A, Bejanyan Nelli, Elmariah Hany

机构信息

Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.

Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.

出版信息

Bone Marrow Transplant. 2025 Jul 5. doi: 10.1038/s41409-025-02670-7.

DOI:10.1038/s41409-025-02670-7
PMID:40617898
Abstract
摘要

相似文献

1
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.来特莫韦可降低接受移植后环磷酰胺治疗的 HLA 匹配和不匹配的异基因造血细胞移植患者的巨细胞病毒感染率。
Bone Marrow Transplant. 2025 Jul 5. doi: 10.1038/s41409-025-02670-7.
2
Letermovir prophylaxis for cytomegalovirus infection in hematopoietic transplantation with post-transplant cyclophosphamide.来特莫韦预防接受移植后环磷酰胺的造血移植受者巨细胞病毒感染。
Medicina (B Aires). 2025;85(3):526-533.
3
Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.来特莫韦用于预防单倍体相合及配型不合的成年供者异基因造血细胞移植中巨细胞病毒再激活，移植后使用环磷酰胺预防移植物抗宿主病。
Transplant Cell Ther. 2021 Jan;27(1):85.e1-85.e6. doi: 10.1016/j.bbmt.2020.10.009. Epub 2020 Oct 11.
4
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide.来特莫韦与高剂量伐昔洛韦预防移植后环磷酰胺治疗的单倍体相合或不合基因相关供者异基因造血细胞移植后巨细胞病毒感染的比较。
Leuk Lymphoma. 2022 Aug;63(8):1925-1933. doi: 10.1080/10428194.2022.2042686. Epub 2022 Feb 20.
5
Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.来特莫韦用于儿童患者异基因造血干细胞移植后巨细胞病毒预防的疗效和安全性
Drug Des Devel Ther. 2025 Jun 12;19:5059-5069. doi: 10.2147/DDDT.S513383. eCollection 2025.
6
Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience.来特莫韦作为异基因造血细胞移植后巨细胞病毒感染的二级预防：单中心经验。
Eur J Haematol. 2024 Oct;113(4):477-484. doi: 10.1111/ejh.14258. Epub 2024 Jun 21.
7
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.异基因干细胞移植后第 100 天停用洛韦特停药与 CMV 相关死亡率增加相关。
Transplant Cell Ther. 2022 Aug;28(8):510.e1-510.e9. doi: 10.1016/j.jtct.2022.05.020. Epub 2022 May 20.
8
Extended duration letermovir in allogeneic hematopoietic stem cell transplant.延长疗程的来特莫韦用于异基因造血干细胞移植。
Transpl Immunol. 2023 Dec;81:101936. doi: 10.1016/j.trim.2023.101936. Epub 2023 Sep 26.
9
Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant.来特莫韦用于阿仑单抗去除T细胞的异基因造血干细胞移植后巨细胞病毒预防的疗效
Transplant Cell Ther. 2024 Dec;30(12):1193.e1-1193.e8. doi: 10.1016/j.jtct.2024.09.009. Epub 2024 Sep 12.
10
Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplant.接受移植后环磷酰胺与基于甲氨蝶呤的移植物抗宿主病预防方案的异基因造血细胞移植患者的嵌合动力学及相关结果比较
Transplant Cell Ther. 2025 Sep;31(9):670.e1-670.e11. doi: 10.1016/j.jtct.2025.05.006. Epub 2025 May 16.

本文引用的文献

1
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.延长疗程乐韦莫韦预防造血干细胞移植受者巨细胞病毒感染的疗效和安全性：一项多中心、随机、双盲、安慰剂对照的 3 期临床试验。
Lancet Haematol. 2024 Feb;11(2):e127-e135. doi: 10.1016/S2352-3026(23)00344-7. Epub 2023 Dec 21.
2
Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide.来特莫韦在异基因造血干细胞移植后环磷酰胺治疗中的疗效。
Int J Hematol. 2023 Sep;118(3):347-354. doi: 10.1007/s12185-023-03635-6. Epub 2023 Jul 19.
3
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
移植后环磷酰胺为基础的移植物抗宿主病预防。
N Engl J Med. 2023 Jun 22;388(25):2338-2348. doi: 10.1056/NEJMoa2215943.
4
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.移植后环磷酰胺与巨细胞病毒感染增加有关：CIBMTR 分析。
Blood. 2021 Jun 10;137(23):3291-3305. doi: 10.1182/blood.2020009362.
5
Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation.单倍体相合供者与脐带血异基因造血细胞移植后的免疫重建
Life (Basel). 2021 Jan 29;11(2):102. doi: 10.3390/life11020102.
6
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒感染。
N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.
7
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.早期巨细胞病毒再激活在当前时代仍与移植相关死亡率增加相关：一项国际骨髓移植登记处（CIBMTR）的分析。
Blood. 2016 May 19;127(20):2427-38. doi: 10.1182/blood-2015-11-679639. Epub 2016 Feb 16.
8
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.非血缘供者移植后经减低强度预处理：使用部分 HLA 错配相关骨髓或无关双脐血移植物的平行 2 期试验结果。
Blood. 2011 Jul 14;118(2):282-8. doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.